Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $7.66, for a total transaction of $87,684.02. Following the completion of the transaction, the director now directly owns 7,229,861 shares of the company's stock, valued at approximately $55,380,735.26. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Blake Borgeson also recently made the following trade(s):
- On Tuesday, April 2nd, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $8.82, for a total transaction of $100,962.54.
- On Tuesday, March 19th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $10.79, for a total transaction of $216,382.66.
- On Tuesday, March 5th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $12.06, for a total transaction of $241,851.24.
- On Tuesday, February 20th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $12.32, for a total transaction of $247,065.28.
- On Tuesday, February 6th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $9.30, for a total transaction of $106,457.10.
- On Tuesday, January 23rd, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $10.58, for a total transaction of $212,171.32.
Recursion Pharmaceuticals Price Performance
Have You Seen Elon’s New A.I. Device? (Picture Inside)
From InvestorPlace | Ad
A strange new era for mankind is upon us...
And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day.
Elon believes A.I. is advancing so fast...
This strange new device to protect us against that A.I. threat...
RXRX opened at $7.40 on Friday. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $4.54 and a fifty-two week high of $16.75. The company's 50 day moving average price is $10.79 and its two-hundred day moving average price is $9.09.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its earnings results on Tuesday, February 27th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.46) by $0.06. Recursion Pharmaceuticals had a negative net margin of 735.99% and a negative return on equity of 72.88%. The firm had revenue of $10.89 million for the quarter, compared to analyst estimates of $12.37 million. Equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.63 EPS for the current year.
Institutional Investors Weigh In On Recursion Pharmaceuticals
Institutional investors have recently added to or reduced their stakes in the business. ARK Investment Management LLC boosted its stake in shares of Recursion Pharmaceuticals by 200.4% in the 4th quarter. ARK Investment Management LLC now owns 20,654,287 shares of the company's stock valued at $203,651,000 after purchasing an additional 13,777,689 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Recursion Pharmaceuticals by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 15,665,210 shares of the company's stock valued at $154,459,000 after purchasing an additional 158,376 shares during the last quarter. Mubadala Investment Co PJSC bought a new stake in shares of Recursion Pharmaceuticals in the 4th quarter valued at $128,041,000. BlackRock Inc. boosted its stake in shares of Recursion Pharmaceuticals by 9.3% in the 2nd quarter. BlackRock Inc. now owns 11,619,427 shares of the company's stock valued at $86,797,000 after purchasing an additional 987,570 shares during the last quarter. Finally, FMR LLC boosted its stake in shares of Recursion Pharmaceuticals by 134.4% in the 3rd quarter. FMR LLC now owns 10,689,532 shares of the company's stock valued at $81,775,000 after purchasing an additional 6,129,935 shares during the last quarter. 89.06% of the stock is owned by institutional investors.
Analyst Ratings Changes
RXRX has been the subject of several analyst reports. KeyCorp boosted their target price on shares of Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an "overweight" rating in a research report on Monday, March 4th. TD Cowen began coverage on shares of Recursion Pharmaceuticals in a research report on Friday, January 26th. They set a "market perform" rating for the company. Finally, Needham & Company LLC reiterated a "buy" rating and set a $17.00 price objective on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 9th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $12.75.
View Our Latest Stock Report on Recursion Pharmaceuticals
About Recursion Pharmaceuticals
(
Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
